PCRX Pacira BioSciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCRX

Price (delayed)

$22.67

Market cap

$892.02M

P/E Ratio

188.92

Dividend/share

N/A

EPS

$0.12

Enterprise value

$1.16B

?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 33
Relative Valuation: Rel. Valuation: 57
Relative Profitability: Rel. Profitability: 62

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local ...

Highlights
The company's quick ratio has surged by 58% YoY
Pacira BioSciences's debt has decreased by 35% YoY
The company's net income has surged by 105% YoY but it fell by 27% QoQ
Pacira BioSciences's EPS has surged by 105% YoY but it has decreased by 25% QoQ
The equity has declined by 18% year-on-year and by 6% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.pacira.com
Peers: HRTX CPIX TVRD OMER

Key stats

What are the main financial stats of PCRX

PCRX stock price

How has the Pacira BioSciences stock price performed over time
Intraday
1.57%
1 week
-4.27%
1 month
-8.18%
1 year
-15.97%
YTD
-12.4%
QTD
0.31%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time
Revenue
$734.86M
Gross profit
$583.01M
Operating income
$24.1M
Net income
$5.14M
Gross margin
79.3%
Net margin
0.7%
The company's operating income has surged by 128% YoY and by 26% QoQ
PCRX's operating margin has soared by 128% YoY and by 27% QoQ
The company's net income has surged by 105% YoY but it fell by 27% QoQ
Pacira BioSciences's net margin has soared by 105% YoY but it has decreased by 30% from the previous quarter

Price vs fundamentals

How does PCRX's price correlate with its fundamentals

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation
PCRX P/E details
P/E
188.92
P/B
1.49
P/S
1.25
EV/EBIT
38.98
EV/EBITDA
9.58
EV/Sales
1.58
Pacira BioSciences's EPS has surged by 105% YoY but it has decreased by 25% QoQ
PCRX's P/B is 36% below its 5-year quarterly average of 2.3 and 2% below its last 4 quarters average of 1.5
The equity has declined by 18% year-on-year and by 6% since the previous quarter
The price to sales (P/S) is 56% lower than the 5-year quarterly average of 2.8 and 18% lower than the last 4 quarters average of 1.5
The revenue has grown by 4.6% YoY

Efficiency

How efficient is Pacira BioSciences business performance
Pacira BioSciences's ROIC has soared by 168% YoY but it has decreased by 10% from the previous quarter
Pacira BioSciences's return on sales has surged by 156% YoY but it has decreased by 15% QoQ
Pacira BioSciences's ROA has soared by 106% YoY but it has decreased by 20% from the previous quarter
PCRX's ROE has soared by 105% year-on-year but it is down by 22% since the previous quarter

Dividends

What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time
The total assets is 118% greater than the total liabilities
The current ratio has soared by 96% YoY and by 4.2% from the previous quarter
The company's quick ratio has surged by 58% YoY
Pacira BioSciences's debt is 37% less than its equity
Pacira BioSciences's debt has decreased by 35% YoY
Pacira BioSciences's debt to equity has decreased by 21% YoY but it has increased by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.